Quartz 5
Search
Search
Dark mode
Light mode
Explorer
Home
❯
Wiki 内容索引
❯
来源
❯
组会文献
组会文献
33 items under this folder.
Jul 18, 2026
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
group-study
her2-positive-breast-cancer
adc
spatial-omics
xenium
neoadjuvant-treatment
Jul 18, 2026
Single-cell RNA sequencing identifies molecular biomarkers predicting late progression to CDK4/6 inhibition in patients with HR+/HER2- metastatic breast cancer
group-study
breast-cancer
single-cell-rna-seq
cdk4-6-inhibitor
Jul 18, 2026
Single cell spatial transcriptomics track the evolutionary hierarchy and microenvironment remodeling during breast carcinoma invasion
group-study
breast-cancer
dcis
spatial-transcriptomics
clonal-evolution
tumor-microenvironment
Jul 17, 2026
乳腺癌 ADC 组会讲解笔记——从精准递送到肿瘤微环境重编程
group-study
presentation
breast-cancer
antibody-drug-conjugate
Jul 17, 2026
Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming
group-study
breast-cancer
antibody-drug-conjugate
Jul 17, 2026
The mechanism of ncRNA in trastuzumab resistance in HER2-positive tumors
group-study
her2-positive-tumor
trastuzumab-resistance
non-coding-rna
Jul 17, 2026
PARP Inhibitors for Breast Cancer Treatment: A Review
group-study
breast-cancer
review
parp-inhibitor
Jul 17, 2026
Multi-omics Analysis Reveals Comprehensive Aberrant Protein and Phosphorylation Characteristics in Breast Cancer and Paired Metastatic Lymph Nodes
group-study
breast-cancer
lymph-node-metastasis
multi-omics
phosphoproteomics
Jul 17, 2026
The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer
group-study
prostate-cancer
nepc
elavl3
mycn
rna-binding-protein
preclinical
Jul 17, 2026
ZNF689 loss impairs homologous recombination sensitizing triple-negative breast cancer to combined PARP and PD-L1 inhibition
group-study
tnbc
znf689
homologous-recombination
parp-inhibitor
pd-l1
Jul 17, 2026
Selective Elimination of Breast Surgery for Invasive Breast Cancer: A Nonrandomized Clinical Trial
group-study
breast-cancer
neoadjuvant-treatment
surgery-omission
vacuum-assisted-biopsy
phase-2
Jul 15, 2026
Extracellular matrix rigidity controls breast cancer metastasis via TYK2-mediated mechanotransduction
group-study
breast-cancer
tnbc
mechanotransduction
tyk2
metastasis
Jul 15, 2026
FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models
group-study
breast-cancer
tnbc
parp-inhibitor
resistance
Jul 15, 2026
HER3 upregulation reduces DS-8201 sensitivity in HER2-positive tumor cells by ATR/CHK1/FoxO1 signaling cascade
group-study
her2-positive-tumor
antibody-drug-conjugate
drug-resistance
Jul 15, 2026
Molecular classification of hormone receptor-positive/HER2-positive breast cancer reveals potential neoadjuvant therapeutic strategies
group-study
hr-positive
her2-positive
breast-cancer
molecular-subtyping
neoadjuvant-treatment
Jul 15, 2026
Understanding and overcoming CDK4/6 inhibitor resistance in HR+/HER2− metastatic breast cancer: clinical and molecular perspectives
group-study
breast-cancer
review
cdk4-6-inhibitor
Jul 15, 2026
P005 组会讲解笔记——单细胞 RNA 测序预测 CDK4/6 抑制剂进展
group-study
presentation
breast-cancer
single-cell-rna-seq
Jul 15, 2026
P006 组会讲解笔记——CDK4/6 抑制剂耐药综述
group-study
presentation
breast-cancer
cdk4-6-inhibitor
Jul 15, 2026
P008 组会讲解笔记——乳腺癌 PARP 抑制剂治疗
group-study
presentation
breast-cancer
parp-inhibitor
Jul 15, 2026
P009 组会讲解笔记——FGFR3–PARP1 磷酸化与 PARP 抑制剂耐药
group-study
presentation
breast-cancer
parp-inhibitor
resistance
Jul 15, 2026
Mitigating T cell DNA damage during PARP inhibitor treatment enhances antitumor efficacy
group-study
ovarian-cancer
parp-inhibitor
t-cell
car-t
Jul 15, 2026
PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer
group-study
review
breast-cancer
hr-positive
pi3k-akt-mtor
Jul 15, 2026
Stabilization of RUNX1 Induced by O-GlcNAcylation Promotes PDGF-BB-Mediated Resistance to CDK4/6 Inhibitors in Breast Cancer
group-study
breast-cancer
basic-research
cdk4-6-inhibitor
Jul 15, 2026
USP10/GSK3β-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer
group-study
breast-cancer
pi3k-inhibitor
pten
resistance
Jul 15, 2026
Combine mitochondrial-targeted gene therapy and chemotherapy to treat triple-negative breast cancer
group-study
tnbc
mitochondria
gene-therapy
parp-inhibitor
preclinical
Jul 15, 2026
Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs
group-study
breast-cancer
pi3k-inhibitor
autophagy
metabolism
Jul 15, 2026
乳腺癌研究 papers：老师文献点评与阅读导引
group-study
teaching-synthesis
literature-digest
teacher-commentary
breast-cancer
Jul 15, 2026
Multiomic integration reveals subtype-specific predictors of neoadjuvant treatment response in breast cancer
group-study
breast-cancer
neoadjuvant-treatment
multi-omics
machine-learning
Jul 15, 2026
Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
group-study
triple-negative-breast-cancer
clinical-trial
antibody-drug-conjugate
Jul 15, 2026
Circulating Tumor DNA in Early Breast Cancer: A Review
group-study
breast-cancer
ctdna
mrd
liquid-biopsy
review
Jul 15, 2026
Cell death in cancer
group-study
review
regulated-cell-death
immunogenic-cell-death
cancer
Jul 15, 2026
Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study
group-study
triple-negative-breast-cancer
retrospective-study
eribulin
Jul 15, 2026
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and/or BRCA mutation-associated breast cancer (S1416): a randomised, phase 2 trial
group-study
tnbc
metastatic-breast-cancer
parp-inhibitor
cisplatin
randomized-trial